The Asacol antitrust class action settlement stemmed from claims that Warner Chilcott, a pharmaceutical manufacturer, engaged in illegal “product hopping”—withdrawing the original Asacol medication from the market just before its patent expired to prevent generic competition, then replacing it with Delzicol, an essentially identical drug with a newly patented delivery capsule. The settlement resolved antitrust allegations under the Sherman Act, with Allergan (Warner Chilcott’s parent company) ultimately paying $2.7 million to three plaintiff organizations in 2018, along with admitting to the monopolization scheme that kept consumers paying premium prices for a brand-name drug that had no meaningful therapeutic advantage over generics that were set to become available.
This case is significant because it represents one of the clearest examples of pharmaceutical product hopping, a practice where manufacturers remove a drug from the market shortly before generic competition arrives and introduce a slightly modified version with a new patent. For patients and consumers who had been prescribed Asacol for ulcerative colitis treatment, the consequence was simple: they were forced to switch to the new Delzicol formulation or seek alternative medications, even though the active ingredient—mesalamine—was identical in both products. The distinction centered on the outer capsule coating, which was the only element that differed between the two drugs.
Table of Contents
- How Does Pharmaceutical Product Hopping Violate Antitrust Laws?
- The Court’s Analysis and Class Certification Reversal
- The Settlement and Direct Purchaser Recovery
- The Broader Federal Healthcare Fraud Settlement
- State-Level Settlements and Consumer Compensation
- What Asacol Treats and Why the Drug Switch Mattered
- Lessons for Pharmaceutical Regulation and Future Litigation
- Conclusion
How Does Pharmaceutical Product Hopping Violate Antitrust Laws?
Product hopping occurs when a manufacturer uses the patent system or FDA approval processes to maintain market dominance and block generic competition, rather than competing on price or innovation. In the Asacol case, the timeline was telling: Warner Chilcott stopped selling and marketing the original Asacol on March 18, 2013. This withdrawal date was strategically significant because Asacol’s patent protection was set to expire just four-and-a-half months later on July 30, 2013. By removing the drug from the market before that patent expiration, Warner Chilcott effectively prevented generic manufacturers from establishing bioequivalence data and launching generic versions when the patent actually expired. The company then replaced Asacol with Delzicol, which contained the same active ingredient mesalamine but featured a new coating designed to address FDA concerns about dibutyl phthalate (DBP) found in the original formulation’s capsule. While the company cited FDA guidance about minimizing DBP exposure, the timing raised questions about whether patient safety was the true driver or merely the justification for a calculated market strategy.
Antitrust courts have long recognized that patent rights are not absolute shields against monopolization claims. The Sherman Act Section 2 prohibits monopolization and attempts to monopolize. When a dominant firm uses patents or regulatory processes not to promote innovation, but to eliminate competition or maintain supracompetitive pricing, it can constitute illegal conduct. In the Asacol case, the district court found that the plaintiffs had sufficiently alleged a Sherman Act Section 2 monopolization claim. The core argument was straightforward: consumers and benefits plans faced a choice between paying premium prices for the brand-name Delzicol or switching to entirely different medications when generics became available at lower cost. Warner Chilcott’s withdrawal of Asacol before generic entry, followed by the introduction of Delzicol with a patent-protected delivery system, created barriers that prevented generic competition from functioning as intended under the Hatch-Waxman Act.
The Court’s Analysis and Class Certification Reversal
The case initially certified a class of indirect purchasers—insurance companies and benefits plans—who had paid elevated prices due to the product hopping scheme. However, on October 15, 2018, the First Circuit Court of Appeals reversed class certification on procedural grounds, finding that the class would be unmanageable. The court’s reasoning hinged on a critical economic question: approximately 10 percent of indirect purchasers would have paid the premium price for the brand-name Delzicol drug even if a generic version had been immediately available at a lower cost. This finding meant that not all class members had been injured in identical ways by the same conduct.
Some purchasers might have selected Delzicol regardless of generic availability, making their damages calculations fundamentally different from those who switched only because no other option existed. This reversal highlighted a persistent challenge in antitrust litigation involving pharmaceutical products: proving that every class member suffered the same injury from the same conduct. Even though the court reversed certification, it notably did not dismiss the underlying Sherman Act Section 2 claim on the merits. The district court’s determination that the plaintiffs had adequately alleged monopolization stood intact. What changed was the procedural vehicle for seeking redress—instead of pursuing the case as a certified class action where certification creates certain procedural advantages and efficiencies, the litigation moved toward individual claims or smaller, more tailored settlements with specific purchasers.
The Settlement and Direct Purchaser Recovery
Rather than continuing to litigate these procedural and damages questions, Allergan agreed to settle with three plaintiff organizations—all union-sponsored benefits plans that had directly purchased Asacol and Delzicol for their members—by paying $2.7 million. The settlement resolved the company’s antitrust liability without an admission that the product hopping actually occurred or that it caused quantifiable damages, which is standard settlement language. However, judgment was entered against Allergan, formally establishing the company’s liability under the Sherman Act, even if the dollar amount may have seemed modest compared to typical pharmaceutical settlements. The $2.7 million figure reflected the specific damages calculations for these three direct purchaser organizations, not a global antitrust settlement covering all consumers affected by the product hopping scheme. Direct purchasers in pharmaceutical cases are typically institutional buyers—hospitals, pharmacy benefit managers, insurance companies, and benefits plans—who negotiate prices with manufacturers.
Because they buy in volume and have more leverage than individual consumers, they often recover at the front end when settlements are reached. Individual patients and consumers who purchased Asacol or Delzicol at pharmacy counters would fall under the category of indirect purchasers. While some states recognize indirect purchaser claims under state law, federal antitrust law provides no private right of action for indirect purchasers. This distinction meant that individual consumers harmed by elevated drug prices had limited avenues for recovery. The $2.7 million settlement primarily addressed the economic injuries of the institutional purchasers, while individual patients’ harm went largely uncompensated in the antitrust context.
The Broader Federal Healthcare Fraud Settlement
Beyond the antitrust settlement, Allergan’s parent company (formerly Warner Chilcott) faced separate federal charges related to the illegal promotion of Asacol and other pharmaceutical products. In a distinct settlement with the U.S. Department of Justice and the U.S. Attorney’s Office, Allergan agreed to pay $125 million to resolve criminal liability and false claims allegations stemming from improper kickbacks to physicians and other illegal promotional practices that occurred between 2009 and 2013. This was a criminal matter, not an antitrust case, and it addressed how the company marketed and promoted Asacol through the Medicaid and Medicare systems via unlawful inducements to prescribers.
The company pleaded guilty to felony health care fraud, making this settlement one of the more significant pharmaceutical criminal resolutions. The distinction between the $2.7 million antitrust settlement and the $125 million healthcare fraud settlement is important for understanding the company’s misconduct. The antitrust case focused on market structure and competition—removing a drug from the market to maintain patent-protected pricing power. The healthcare fraud case focused on how the company illegally paid off doctors and induced them to prescribe medications through kickback schemes in federal healthcare programs. While both cases involved Asacol and overlapped in time period, they represented different violations of law with different remedies. The much larger $125 million criminal settlement reflected the broader scope of healthcare fraud involving multiple drugs and multiple years of improper conduct.
State-Level Settlements and Consumer Compensation
California brought its own enforcement action related to the same conduct, resulting in a separate settlement that yielded $23.2 million in total payments. Of this amount, $11.8 million went to the State of California for fraud prevention and consumer protection efforts. This state-level enforcement filled a gap that federal antitrust law could not address, as states can bring claims on behalf of their citizens for consumer protection violations and fraud related to pharmaceutical pricing. California’s settlement provided direct compensation and deterrence at the state level, though details about how that $11.8 million was distributed to consumers or used for consumer protection purposes vary by the terms of the settlement agreement.
One limitation of settling antitrust and fraud cases through state enforcement is that recovery amounts are often directed toward state treasury accounts, legal fees, or future prevention programs rather than direct compensation to harmed consumers. Individual patients who took Asacol or Delzicol during the period when the product hopping occurred may have had no direct way to recover their overpayments. If they were covered by Medicare or Medicaid, some of that fraud settlement amount theoretically flows back to those federal programs, but individual policyholders rarely see direct refunds. For privately insured consumers, the recovery typically benefits the insurance plan or benefits plan itself, which may or may not pass savings on to enrollees through lower premiums or out-of-pocket costs.
What Asacol Treats and Why the Drug Switch Mattered
Asacol and Delzicol are both brand-name formulations of mesalamine, an anti-inflammatory medication used to treat ulcerative colitis—a chronic inflammatory bowel disease affecting the colon and rectum. For patients whose condition was stable on Asacol, the forced switch to Delzicol created unnecessary disruption and risk. While the active ingredient was identical, patients understandably worried about tolerability and efficacy differences, even if the FDA considered the products bioequivalent. Some patients reported difficulty with the transition, and the psychological burden of switching medications involuntarily added to the burden of managing a chronic illness.
Additionally, Delzicol’s higher cost reflected Warner Chilcott’s patent protection on the new capsule design, meaning patients faced the choice of either accepting the medication switch or trying entirely different drug classes or treatments. Generic mesalamine became available after Asacol’s patent expired, providing patients and insurers with a significantly cheaper alternative. However, some patients and prescribers showed reluctance to switch to generics, partly due to brand loyalty but also due to concerns about formulation differences. Asacol’s original enteric-coated formulation was designed to release mesalamine in a specific part of the intestine, and some generics vary slightly in their delivery characteristics. This illustrates a real-world consequence of product hopping: it forces patients and healthcare systems into medication transitions that may be medically unnecessary and creates opportunities for further market segmentation and premium pricing.
Lessons for Pharmaceutical Regulation and Future Litigation
The Asacol antitrust case contributed to the legal framework governing product hopping and provided guidance to future plaintiffs about how to plead such claims. By the time the First Circuit issued its 2018 decision, multiple circuits had begun to recognize product hopping as a viable antitrust theory under Section 2 of the Sherman Act. The case demonstrated that courts would take seriously allegations that a pharmaceutical company strategically removed a drug from the market timed to prevent generic entry, even if the company’s stated justification involved FDA safety guidance. However, the reversal of class certification also signaled that procedural barriers and damages calculations could prevent large-scale aggregate recovery even where liability is established.
Looking forward, the Asacol settlement and similar product hopping cases have influenced how pharmaceutical companies structure product transitions and how regulators view withdrawal decisions. The FTC and state attorneys general have become more vigilant about product hopping schemes, recognizing them as a form of competition harm distinct from traditional patent disputes. However, the reality remains that individual consumers who purchase medications at retail prices rarely benefit directly from antitrust recoveries, which tend to flow to institutional purchasers, state agencies, or federal programs. For patients dependent on medications like mesalamine for serious chronic conditions, the broader lesson is that patent law and market concentration in pharmaceuticals can create situations where competition fails to deliver lower prices or better options, and legal interventions, while important, may occur too late to prevent years of consumer harm.
Conclusion
The Asacol digestive drug antitrust class action settlement resolved claims that Warner Chilcott engaged in illegal product hopping—removing the original Asacol from the market shortly before its patent expired to prevent generic competition, then replacing it with Delzicol, a drug with an identical active ingredient but a newly patented capsule design. The $2.7 million antitrust settlement to direct purchasers and the separate $125 million federal healthcare fraud settlement illustrated that the company’s conduct violated multiple areas of law, from competition law to healthcare program integrity. Together with California’s $23.2 million settlement, these resolutions established Allergan’s liability and provided some deterrent effect against similar schemes in the pharmaceutical industry.
If you were a patient or consumer who took Asacol or Delzicol during the product hopping period, or if your health insurance or benefits plan purchased these medications, you may have been affected by the overcharges that resulted. While direct purchaser benefits plans recovered through the $2.7 million antitrust settlement, individual consumer recovery is limited. Understanding this case is valuable as an illustration of how patent law and regulatory processes can be used strategically to block competition, and why pharmaceutical pricing remains a critical policy issue despite antitrust enforcement efforts.